The Impact of the US Priority Review Voucher on Private-Sector Investment in Global Health Research and Development

PLoS Neglected Tropical Diseases

Volumn 6, Issue 8, 2012, Pages

  Robertson, Andrew S ^a   Stefanakis, Rianna ^a   Joseph, Don ^a   Moree, Melinda ^a  

^a BIO Ventures for Global Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST; DRUG APPROVAL; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HEALTH PROGRAM; HUMAN; INVESTMENT; MARKETING; MEDICAL RESEARCH; NEGLECTED DISEASE; ORGANIZATION AND MANAGEMENT; PERSONNEL MANAGEMENT; PRIORITY REVIEW VOUCHER PROGRAM; RESEARCH PRIORITY; TROPICAL DISEASE; UNITED STATES;

BIOMEDICAL RESEARCH; COMMUNICABLE DISEASES; HEALTH POLICY; HUMANS; INFECTION CONTROL; INVESTMENTS; NEGLECTED DISEASES; PRIVATE SECTOR; RESEARCH; UNITED STATES; WORLD HEALTH;

EID: 84865967881     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001750     Document Type: Article

References (19)

1. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, et al. (2002) Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 359 (9324) (): 2188-2194.
2. World Health Organization (2004) Disease and injury regional estimates for 2004.
3. World Health Organization (2009) Neglected tropical diseases: hidden successes, emerging opportunities.
4. Cohen J, Dibner MS, Wilson A, (2010) Development of and access to products for neglected diseases. PLoS ONE 5 (5) (): e10610 doi:10.1371/journal.pone.0010610.
5. Moran M, Guzman J, Ropars AL, McDonald A, Jameson N, et al. (2009) Neglected disease research and development: how much are we really spending? PLoS Med 6 (2) (): e1000030 doi:10.1371/journal.pmed.1000030.
6. Towse A, Kettler H, (2005) Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies. Bull World Health Organ 83 (4) (): 301-307.
7. "Priority Review to Encourage Treatments for Tropical Diseases," Title 21, U.S. Code, Pts. 360n, 2007 ed. Available: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FoodandDrugAdministrationAmendmentsActof2007/FullTextofFDAAALaw/default.htm. Accessed 4 Jan 2012.
8. U.S. Food and Drug Administration. FDA Draft Guidance for Industry: Tropical Disease Priority Review Vouchers. Washington: Government Printing Office, October 2008.
9. Ridley D, Grabowski H, Moe J, (2006) Developing drugs for developing countries. Health Affairs 25 (2) (): 313-324.
10. Noor W, (2009) Placing value on FDA's priority review vouchers. In Vivo: The Business Medicine Report 27 (8) (): 1-8.
11. Gingery D, (2010) Priority review voucher's uncertain value may hinder development. The Pink Sheet 72 (8) ().
12. Kesselheim A, (2008) Drug development for neglected diseases-the trouble with FDA review vouchers. N Engl J Med 359: 1981-1983.
13. The Pink Sheet Daily (June 2011) Ilaris safety data inadequate for gout indication.
14. Novartis Press Release, "FDA requests additional clinical data on Novartis drug ACZ885 for the treatment of gouty arthritis," (Aug 29, 2011).
15. "Global Health Primer," BIO Ventures for Global Health. Available: http://www.bvgh.org/GlobalHealthPrimer.aspx. Accessed 15 July 2011.
16. "Fee for Using a Priority Review Voucher in Fiscal Year 2012." The Federal Register. 76:168 (Aug 30, 2011) p. 53910-53912.
17. Anderson T, (2009) Novartis under fire for accepting new reward for old drug. Lancet 373 (9673) (): 1414.
18. (2011) The Creating Hope Act of 2011, S. 606. 112th Congress, 1st Session. Washington, DC: U.S. Senate. Available: http://www.govtrack.us/congress/bills/112/s606. Accessed 7 August 2012.
19. Jack A (2008 April 30) FDA to aid tropical disease research. Financial Times. Available: http://www.ft.com/intl/cms/s/0/3b6f77aa-16f2-11dd-bbfc-0000779fd2ac.html#axzz1iWFfBAd8. Accessed 4 Jan 2012.